162 related articles for article (PubMed ID: 20956959)
41. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
43. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
44. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
45. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
[TBL] [Abstract][Full Text] [Related]
46. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
48. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.
Peres E; Braun T; Krijanovski O; Khaled Y; Levine JE; Yanik G; Kato K; Mineishi S
Bone Marrow Transplant; 2009 Nov; 44(9):579-83. PubMed ID: 19308041
[TBL] [Abstract][Full Text] [Related]
49. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
50. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
Yanada M; Naoe T; Iida H; Sakamaki H; Sakura T; Kanamori H; Kodera Y; Okamoto S; Kanda Y; Sao H; Asai O; Nakai K; Maruta A; Kishi K; Furukawa T; Atsuta Y; Yamamoto K; Tanaka J; Takahashi S
Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
[TBL] [Abstract][Full Text] [Related]
51. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis.
Dreger P; Brand R; Milligan D; Corradini P; Finke J; Lambertenghi Deliliers G; Martino R; Russell N; van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2005 Jun; 19(6):1029-33. PubMed ID: 15830011
[TBL] [Abstract][Full Text] [Related]
52. Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Piñana JL; Sanz J; Esquirol A; Martino R; Picardi A; Barba P; Parody R; Gayoso J; Montesinos P; Guidi S; Terol MJ; Moscardó F; Solano C; Arcese W; Sanz MA; Sierra J; Sanz G;
Eur J Haematol; 2016 Feb; 96(2):128-35. PubMed ID: 25845981
[TBL] [Abstract][Full Text] [Related]
53. Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT.
Castagna L; Fürst S; Marchetti N; El Cheikh J; Faucher C; Mohty M; Bouabdallah R; Vey N; Stoppa AM; Esterni B; Blaise D
Bone Marrow Transplant; 2011 Jul; 46(7):1000-5. PubMed ID: 20921945
[TBL] [Abstract][Full Text] [Related]
54. Is there a role for reduced-intensity haematopoietic stem cell transplantation for indolent non-Hodgkin's lymphoma?
Ho AY; Pagliuca A
Hematology; 2002 Dec; 7(6):345-54. PubMed ID: 12475739
[TBL] [Abstract][Full Text] [Related]
55. Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning.
Barba P; Martino R; Perez-Simón JA; Fernández-Avilés F; Piñana JL; Valcárcel D; Campos-Varela I; Lopez-Anglada L; Rovira M; Novelli S; Lopez-Corral L; Carreras E; Sierra J
Bone Marrow Transplant; 2012 Oct; 47(10):1343-9. PubMed ID: 22388280
[TBL] [Abstract][Full Text] [Related]
56. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P
Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949
[TBL] [Abstract][Full Text] [Related]
57. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.
Robinson SP; Sureda A; Canals C; Russell N; Caballero D; Bacigalupo A; Iriondo A; Cook G; Pettitt A; Socie G; Bonifazi F; Bosi A; Michallet M; Liakopoulou E; Maertens J; Passweg J; Clarke F; Martino R; Schmitz N;
Haematologica; 2009 Feb; 94(2):230-8. PubMed ID: 19066328
[TBL] [Abstract][Full Text] [Related]
58. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Poiré X; Gac AC; Leclerc M; Guillaume T; Chalandon Y; Nguyen S; Forcade E; Régny C; Bay JO; Bazarbachi A; Rohrlich PS; Huynh A; Farhi J; Marchand T; Malfuson JV; Pilorge S; Labussière-Wallet H; Renard C; Fornecker LM; Detrait M; Duléry R; Delage J; Ménard AL; Charbonnier A; Nelken B; Jubert C; Suarez F; de la Tour RP; Beguin Y; Schoemans H; Blaise D; Yakoub-Agha I
Bone Marrow Transplant; 2018 Apr; 53(4):400-409. PubMed ID: 29330405
[TBL] [Abstract][Full Text] [Related]
59. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
Gutiérrez-García G; Martínez C; Boumendil A; Finel H; Malladi R; Afanasyev B; Tsoulkani A; Wilson KMO; Bloor A; Nikoloudis M; Richardson D; López-Corral L; Castagna L; Cornelissen J; Giltat A; Collin M; Fanin R; Bonifazi F; Robinson S; Montoto S; Peggs KS; Sureda A
Br J Haematol; 2022 Feb; 196(4):1018-1030. PubMed ID: 34750806
[TBL] [Abstract][Full Text] [Related]
60. Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE; Dybedal I; Holte H; Heldal D; Torfoss D; Aurlien E; Lauritzsen GF; Fosså A; Lehne G; Baggerød E; Kvalheim G; Egeland T; Bishop MR; Fowler DH; Kolstad A
Bone Marrow Transplant; 2012 Dec; 47(12):1552-7. PubMed ID: 22522568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
